Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Movantik
Pharma
Grünenthal acquires Valinor Pharma and Movantik for $250M
Grünenthal has continued its expansion splurge, acquiring Valinor Pharma and its lone commercial product Movantik for $250 million.
Kevin Dunleavy
Jul 22, 2024 11:12am
AstraZeneca offloads most global rights for GI med Movantik
Feb 25, 2020 11:24am
Daiichi exits U.S. pain market by ending AZ, Inspirion deals
Nov 4, 2019 10:14am
Bad press isn't so bad when it's building a market, AZ says
Apr 10, 2017 10:01am
AZ inks $250M Zoladex deal in latest closet cleanout
Feb 21, 2017 7:39am
Valeant's Relistor a future blockbuster? Analysts aren't buying it
Jul 24, 2016 10:31pm
